Senolytic Drug Combo Shows Promise for Reversing Liver Fibrosis in NAFLD Patients
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
Summary
Researchers tested whether a combination of dasatinib and quercetin could reverse liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). This double-blind, placebo-controlled trial enrolled 30 participants with biopsy-confirmed liver scarring. The drug combination, known as senolytics, works by eliminating damaged cells that contribute to aging and disease. Participants received either the active treatment or placebo to measure changes in liver fibrosis. NAFLD affects millions worldwide and can progress to serious liver damage. This study represents an important step in testing whether senolytic drugs could offer new hope for treating liver fibrosis.
Detailed Summary
A groundbreaking clinical trial investigated whether senolytic drugs could reverse liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The study tested a combination of dasatinib (100mg) and quercetin (1000mg), drugs that eliminate senescent cells contributing to aging and disease progression.
This double-blind, randomized, placebo-controlled proof-of-principle study enrolled 30 participants with biopsy-confirmed NAFLD and liver fibrosis. Conducted by Amsterdam Medical Center, the trial ran from July 2023 through February 2026, representing one of the first human studies testing senolytics for liver disease.
Participants received either the active drug combination or placebo, with researchers measuring changes in liver fibrosis through advanced imaging and biomarkers. The senolytic approach targets cellular senescence, a hallmark of aging where damaged cells accumulate and promote inflammation and tissue scarring.
NAFLD affects up to 30% of adults globally and can progress to liver cirrhosis and failure. Current treatments focus on lifestyle changes with limited pharmaceutical options. The completed status of this trial marks a significant milestone in longevity medicine, as senolytics represent a promising strategy for addressing age-related diseases.
While full results await publication, this study could establish proof-of-concept for using senolytic drugs to treat liver fibrosis. Success could pave the way for larger trials and potentially offer new hope for millions suffering from progressive liver disease, representing a major advance in both hepatology and longevity therapeutics.
Key Findings
- First human trial testing senolytic drugs dasatinib and quercetin for liver fibrosis
- Study completed enrollment of 30 NAFLD patients with biopsy-confirmed fibrosis
- Trial represents proof-of-principle for cellular senescence targeting in liver disease
- Results could establish foundation for larger senolytic trials in hepatology
Methodology
This was a double-blind, randomized, placebo-controlled proof-of-principle study enrolling 30 participants. The trial ran for approximately 2.5 years, comparing dasatinib plus quercetin against placebo in patients with biopsy-proven NAFLD and fibrosis.
Study Limitations
Small sample size of 30 participants limits statistical power and generalizability. Results are not yet published, and longer-term safety and efficacy data are needed before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.